http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 06 Mar 2026 07:05:36 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+PT+Change/GH+Research+PLC+%28GHRS%29+PT+Raised+to+%2432+at+Needham/26122104.html (Updated - March 6, 2026 7:05 AM EST) <p>Needham analyst Ami Fadia raised the price target on GH Research PLC (NASDAQ: GHRS) to $32.00 (from $31.00) while maintaining a Buy rating.</p><p>The analyst commented: "GHRS reported its 4Q25 earnings this morning (LINK) where the 4Q25 EPS of -$0.22 was slightly higher than cons. of -$0.27, due non-operating items, with expenses coming in-line with expectations. Management reiterated that the Ph 3 program in TRD is on track to be initiated in 2026 following FDA clearance of the IND in Jan (LINK). The key gating factor ahead of the Ph 3 initiation is the http://www.streetinsider.com/Analyst+PT+Change/GH+Research+PLC+%28GHRS%29+PT+Raised+to+%2432+at+Needham/26122104.html Fri, 06 Mar 2026 07:05:36 -0500 GHRS http://www.streetinsider.com/Analyst+Comments/GH+Research+PLC+%28GHRS%29+PT+Raised+to+%2432+at+Needham/26122104.html (Updated - March 6, 2026 7:05 AM EST) <p>Needham analyst Ami Fadia raised the price target on GH Research PLC (NASDAQ: GHRS) to $32.00 (from $31.00) while maintaining a Buy rating.</p><p>The analyst commented: "GHRS reported its 4Q25 earnings this morning (LINK) where the 4Q25 EPS of -$0.22 was slightly higher than cons. of -$0.27, due non-operating items, with expenses coming in-line with expectations. Management reiterated that the Ph 3 program in TRD is on track to be initiated in 2026 following FDA clearance of the IND in Jan (LINK). The key gating factor ahead of the Ph 3 initiation is the http://www.streetinsider.com/Analyst+Comments/GH+Research+PLC+%28GHRS%29+PT+Raised+to+%2432+at+Needham/26122104.html Fri, 06 Mar 2026 07:05:36 -0500 GHRS http://www.streetinsider.com/Analyst+PT+Change/GH+Research+PLC+%28GHRS%29+PT+Raised+to+%2442+at+Citizens%3B+Can+Execute+Development+Plans/26121404.html <p>Citizens analyst Jason Butler raised the price target on GH Research PLC (NASDAQ: GHRS) to $42.00 (from $39.00) while maintaining a Market Outperform rating.</p><p>The analyst commented, "GH001 advancing to Phase 3 initiation; we reiterate our Market Outperform rating and increase our risk-adjusted, DCF-derived price target to $42 from $39 on GH Research. Yesterday, GH Research reported 4Q25 financial results and business updates highlighting ongoing development progress for GH001. The clinical hold for GH001 has been lifted, and the company is actively engaging with the FDA to align on a Phase 3 trial design, which would enable a study start in http://www.streetinsider.com/Analyst+PT+Change/GH+Research+PLC+%28GHRS%29+PT+Raised+to+%2442+at+Citizens%3B+Can+Execute+Development+Plans/26121404.html Fri, 06 Mar 2026 04:44:34 -0500 GHRS http://www.streetinsider.com/Analyst+Comments/GH+Research+PLC+%28GHRS%29+PT+Raised+to+%2442+at+Citizens%3B+Can+Execute+Development+Plans/26121404.html <p>Citizens analyst Jason Butler raised the price target on GH Research PLC (NASDAQ: GHRS) to $42.00 (from $39.00) while maintaining a Market Outperform rating.</p><p>The analyst commented, "GH001 advancing to Phase 3 initiation; we reiterate our Market Outperform rating and increase our risk-adjusted, DCF-derived price target to $42 from $39 on GH Research. Yesterday, GH Research reported 4Q25 financial results and business updates highlighting ongoing development progress for GH001. The clinical hold for GH001 has been lifted, and the company is actively engaging with the FDA to align on a Phase 3 trial design, which would enable a study start in http://www.streetinsider.com/Analyst+Comments/GH+Research+PLC+%28GHRS%29+PT+Raised+to+%2442+at+Citizens%3B+Can+Execute+Development+Plans/26121404.html Fri, 06 Mar 2026 04:44:34 -0500 GHRS http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++GH+Research+PLC++++++++++++++++++++++/26115731.html si-local-file:///var/storage/secattach/20260305/26115731.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++GH+Research+PLC++++++++++++++++++++++/26115731.html Thu, 05 Mar 2026 08:31:00 -0500 GHRS O.50288575 http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++GH+Research+PLC++++++++++++++++++++++/26115731.html si-local-file:///var/storage/secattach/20260305/26115731.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++GH+Research+PLC++++++++++++++++++++++/26115731.html Thu, 05 Mar 2026 08:31:00 -0500 GHRS O.50288575 http://www.streetinsider.com/SEC+Filings/Form++20-F+++++++GH+Research+PLC+++++++++++For%3A+Dec+31/26115002.html si-local-file:///var/storage/secattach/20260305/26115002.html http://www.streetinsider.com/SEC+Filings/Form++20-F+++++++GH+Research+PLC+++++++++++For%3A+Dec+31/26115002.html Thu, 05 Mar 2026 07:11:00 -0500 GHRS O.50288575 http://www.streetinsider.com/SEC+Filings/Form++20-F+++++++GH+Research+PLC+++++++++++For%3A+Dec+31/26115002.html si-local-file:///var/storage/secattach/20260305/26115002.html http://www.streetinsider.com/SEC+Filings/Form++20-F+++++++GH+Research+PLC+++++++++++For%3A+Dec+31/26115002.html Thu, 05 Mar 2026 07:11:00 -0500 GHRS O.50288575 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++GH+Research+PLC+++++++++++For%3A+Mar+05/26114969.html si-local-file:///var/storage/secattach/20260305/26114969.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++GH+Research+PLC+++++++++++For%3A+Mar+05/26114969.html Thu, 05 Mar 2026 07:05:00 -0500 GHRS O.50288575 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++GH+Research+PLC+++++++++++For%3A+Mar+05/26114969.html si-local-file:///var/storage/secattach/20260305/26114969.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++GH+Research+PLC+++++++++++For%3A+Mar+05/26114969.html Thu, 05 Mar 2026 07:05:00 -0500 GHRS O.50288575 http://www.streetinsider.com/Corporate+News/GH+Research+reports+phase+2b+depression+trial+success%2C+FDA+clearance/26114922.html <p>GH Research PLC (NASDAQ: GHRS) reported full-year 2025 financial results and announced completion of its Phase 2b trial for GH001 in treatment-resistant depression. The company posted a net loss of $48.3 million, or $0.79 per share, compared to a net loss of $39.0 million, or $0.75 per share, in 2024.</p> <p>The Phase 2b trial met its primary endpoint with a placebo-adjusted Montgomery-Åsberg Depression Rating Scale reduction of -15.5 points at Day 8. In the double-blind portion, 57.5% of patients on GH001 achieved remission versus 0% on placebo. The open-label extension showed a 73% remission rate at six months with infrequent retreatment http://www.streetinsider.com/Corporate+News/GH+Research+reports+phase+2b+depression+trial+success%2C+FDA+clearance/26114922.html Thu, 05 Mar 2026 07:01:22 -0500 A.06822034 GHRS O.20026344 O.50288575 http://www.streetinsider.com/Corporate+News/GH+Research+reports+phase+2b+depression+trial+success%2C+FDA+clearance/26114922.html <p>GH Research PLC (NASDAQ: GHRS) reported full-year 2025 financial results and announced completion of its Phase 2b trial for GH001 in treatment-resistant depression. The company posted a net loss of $48.3 million, or $0.79 per share, compared to a net loss of $39.0 million, or $0.75 per share, in 2024.</p> <p>The Phase 2b trial met its primary endpoint with a placebo-adjusted Montgomery-Åsberg Depression Rating Scale reduction of -15.5 points at Day 8. In the double-blind portion, 57.5% of patients on GH001 achieved remission versus 0% on placebo. The open-label extension showed a 73% remission rate at six months with infrequent retreatment http://www.streetinsider.com/Corporate+News/GH+Research+reports+phase+2b+depression+trial+success%2C+FDA+clearance/26114922.html Thu, 05 Mar 2026 07:01:22 -0500 A.06822034 GHRS O.20026344 O.50288575 http://www.streetinsider.com/Corporate+News/GH+Research+reports+phase+2b+depression+trial+success%2C+FDA+clearance/26114922.html <p>GH Research PLC (NASDAQ: GHRS) reported full-year 2025 financial results and announced completion of its Phase 2b trial for GH001 in treatment-resistant depression. The company posted a net loss of $48.3 million, or $0.79 per share, compared to a net loss of $39.0 million, or $0.75 per share, in 2024.</p> <p>The Phase 2b trial met its primary endpoint with a placebo-adjusted Montgomery-Åsberg Depression Rating Scale reduction of -15.5 points at Day 8. In the double-blind portion, 57.5% of patients on GH001 achieved remission versus 0% on placebo. The open-label extension showed a 73% remission rate at six months with infrequent retreatment http://www.streetinsider.com/Corporate+News/GH+Research+reports+phase+2b+depression+trial+success%2C+FDA+clearance/26114922.html Thu, 05 Mar 2026 07:01:22 -0500 A.06822034 GHRS O.20026344 O.50288575 http://www.streetinsider.com/Corporate+News/GH+Research+reports+phase+2b+depression+trial+success%2C+FDA+clearance/26114922.html <p>GH Research PLC (NASDAQ: GHRS) reported full-year 2025 financial results and announced completion of its Phase 2b trial for GH001 in treatment-resistant depression. The company posted a net loss of $48.3 million, or $0.79 per share, compared to a net loss of $39.0 million, or $0.75 per share, in 2024.</p> <p>The Phase 2b trial met its primary endpoint with a placebo-adjusted Montgomery-Åsberg Depression Rating Scale reduction of -15.5 points at Day 8. In the double-blind portion, 57.5% of patients on GH001 achieved remission versus 0% on placebo. The open-label extension showed a 73% remission rate at six months with infrequent retreatment http://www.streetinsider.com/Corporate+News/GH+Research+reports+phase+2b+depression+trial+success%2C+FDA+clearance/26114922.html Thu, 05 Mar 2026 07:01:22 -0500 A.06822034 GHRS O.20026344 O.50288575 http://www.streetinsider.com/Press+Releases/GH+Research+Reports+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26114892.html <ul type="disc"><li style="margin-bottom:10pt;">Completed Phase 2b trial of GH001 in TRD and presented the full dataset at the 2025 ASCP and ECNP congresses</li><li style="margin-bottom:10pt;">GH001 cleared by FDA for U.S. clinical investigation, enabling U.S. subject enrollment</li><li>Cash, cash equivalents and marketable securities of $280.7 million as of December 31, 2025<br/></li></ul> <p align="justify">DUBLIN, Ireland, March 05, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported financial results for the year ended December 31, 2025, and provided a business update.</p> <p http://www.streetinsider.com/Press+Releases/GH+Research+Reports+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26114892.html Thu, 05 Mar 2026 07:00:00 -0500 A.06822034 GHRS O.20026344 O.50288575 http://www.streetinsider.com/Press+Releases/GH+Research+Reports+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26114892.html <ul type="disc"><li style="margin-bottom:10pt;">Completed Phase 2b trial of GH001 in TRD and presented the full dataset at the 2025 ASCP and ECNP congresses</li><li style="margin-bottom:10pt;">GH001 cleared by FDA for U.S. clinical investigation, enabling U.S. subject enrollment</li><li>Cash, cash equivalents and marketable securities of $280.7 million as of December 31, 2025<br/></li></ul> <p align="justify">DUBLIN, Ireland, March 05, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported financial results for the year ended December 31, 2025, and provided a business update.</p> <p http://www.streetinsider.com/Press+Releases/GH+Research+Reports+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26114892.html Thu, 05 Mar 2026 07:00:00 -0500 A.06822034 GHRS O.20026344 O.50288575 http://www.streetinsider.com/Press+Releases/GH+Research+Reports+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26114892.html <ul type="disc"><li style="margin-bottom:10pt;">Completed Phase 2b trial of GH001 in TRD and presented the full dataset at the 2025 ASCP and ECNP congresses</li><li style="margin-bottom:10pt;">GH001 cleared by FDA for U.S. clinical investigation, enabling U.S. subject enrollment</li><li>Cash, cash equivalents and marketable securities of $280.7 million as of December 31, 2025<br/></li></ul> <p align="justify">DUBLIN, Ireland, March 05, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported financial results for the year ended December 31, 2025, and provided a business update.</p> <p http://www.streetinsider.com/Press+Releases/GH+Research+Reports+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26114892.html Thu, 05 Mar 2026 07:00:00 -0500 A.06822034 GHRS O.20026344 O.50288575 http://www.streetinsider.com/Press+Releases/GH+Research+Reports+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26114892.html <ul type="disc"><li style="margin-bottom:10pt;">Completed Phase 2b trial of GH001 in TRD and presented the full dataset at the 2025 ASCP and ECNP congresses</li><li style="margin-bottom:10pt;">GH001 cleared by FDA for U.S. clinical investigation, enabling U.S. subject enrollment</li><li>Cash, cash equivalents and marketable securities of $280.7 million as of December 31, 2025<br/></li></ul> <p align="justify">DUBLIN, Ireland, March 05, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported financial results for the year ended December 31, 2025, and provided a business update.</p> <p http://www.streetinsider.com/Press+Releases/GH+Research+Reports+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26114892.html Thu, 05 Mar 2026 07:00:00 -0500 A.06822034 GHRS O.20026344 O.50288575 http://www.streetinsider.com/Globe+Newswire/GH+Research+Reports+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26114892.html <ul type="disc"><li style="margin-bottom:10pt;">Completed Phase 2b trial of GH001 in TRD and presented the full dataset at the 2025 ASCP and ECNP congresses</li><li style="margin-bottom:10pt;">GH001 cleared by FDA for U.S. clinical investigation, enabling U.S. subject enrollment</li><li>Cash, cash equivalents and marketable securities of $280.7 million as of December 31, 2025<br/></li></ul> <p align="justify">DUBLIN, Ireland, March 05, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported financial results for the year ended December 31, 2025, and provided a business update.</p> <p http://www.streetinsider.com/Globe+Newswire/GH+Research+Reports+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26114892.html Thu, 05 Mar 2026 07:00:00 -0500 A.06822034 GHRS O.20026344 O.50288575 http://www.streetinsider.com/Globe+Newswire/GH+Research+Reports+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26114892.html <ul type="disc"><li style="margin-bottom:10pt;">Completed Phase 2b trial of GH001 in TRD and presented the full dataset at the 2025 ASCP and ECNP congresses</li><li style="margin-bottom:10pt;">GH001 cleared by FDA for U.S. clinical investigation, enabling U.S. subject enrollment</li><li>Cash, cash equivalents and marketable securities of $280.7 million as of December 31, 2025<br/></li></ul> <p align="justify">DUBLIN, Ireland, March 05, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported financial results for the year ended December 31, 2025, and provided a business update.</p> <p http://www.streetinsider.com/Globe+Newswire/GH+Research+Reports+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26114892.html Thu, 05 Mar 2026 07:00:00 -0500 A.06822034 GHRS O.20026344 O.50288575 http://www.streetinsider.com/Globe+Newswire/GH+Research+Reports+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26114892.html <ul type="disc"><li style="margin-bottom:10pt;">Completed Phase 2b trial of GH001 in TRD and presented the full dataset at the 2025 ASCP and ECNP congresses</li><li style="margin-bottom:10pt;">GH001 cleared by FDA for U.S. clinical investigation, enabling U.S. subject enrollment</li><li>Cash, cash equivalents and marketable securities of $280.7 million as of December 31, 2025<br/></li></ul> <p align="justify">DUBLIN, Ireland, March 05, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported financial results for the year ended December 31, 2025, and provided a business update.</p> <p http://www.streetinsider.com/Globe+Newswire/GH+Research+Reports+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26114892.html Thu, 05 Mar 2026 07:00:00 -0500 A.06822034 GHRS O.20026344 O.50288575 http://www.streetinsider.com/Globe+Newswire/GH+Research+Reports+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26114892.html <ul type="disc"><li style="margin-bottom:10pt;">Completed Phase 2b trial of GH001 in TRD and presented the full dataset at the 2025 ASCP and ECNP congresses</li><li style="margin-bottom:10pt;">GH001 cleared by FDA for U.S. clinical investigation, enabling U.S. subject enrollment</li><li>Cash, cash equivalents and marketable securities of $280.7 million as of December 31, 2025<br/></li></ul> <p align="justify">DUBLIN, Ireland, March 05, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported financial results for the year ended December 31, 2025, and provided a business update.</p> <p http://www.streetinsider.com/Globe+Newswire/GH+Research+Reports+Full+Year+2025+Financial+Results+and+Provides+Business+Update/26114892.html Thu, 05 Mar 2026 07:00:00 -0500 A.06822034 GHRS O.20026344 O.50288575 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++GH+Research+PLC++++++++++++++++++++++++Filed+by%3A+Lynx1+Capital+Management+LP/26010793.html si-local-file:///var/storage/secattach/20260217/26010793.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++GH+Research+PLC++++++++++++++++++++++++Filed+by%3A+Lynx1+Capital+Management+LP/26010793.html Tue, 17 Feb 2026 13:46:00 -0500 GHRS O.50288575 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++GH+Research+PLC++++++++++++++++++++++++Filed+by%3A+Lynx1+Capital+Management+LP/26010793.html si-local-file:///var/storage/secattach/20260217/26010793.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++GH+Research+PLC++++++++++++++++++++++++Filed+by%3A+Lynx1+Capital+Management+LP/26010793.html Tue, 17 Feb 2026 13:46:00 -0500 GHRS O.50288575 http://www.streetinsider.com/Analyst+PT+Change/GH+Research+PLC+%28GHRS%29+PT+Raised+at+RBC+Capital+Following+Psychedelics+Symposium/25884173.html <p>RBC Capital analyst Brian Abrahams raised the price target on GH Research PLC (NASDAQ: GHRS) to $40.00 (from $33.00) while maintaining an Outperform rating.</p><p>The analyst commented: "Raising Price Target to $40 Following Psychedelics Symposium and Reiterating Outperform; Following our Psychedelics Symposium and discussions with mgmt, payers, and docs, we are increasingly optimistic on GHRS's longterm sales opportunity with GH001 and are raising our price target to $40 from $33 based on updated assumptions about drug pricing in-line with Spravato. With EoP2 meeting later this year and pivotal trials initiation on track for later this year, we believe that GHRS remains http://www.streetinsider.com/Analyst+PT+Change/GH+Research+PLC+%28GHRS%29+PT+Raised+at+RBC+Capital+Following+Psychedelics+Symposium/25884173.html Fri, 23 Jan 2026 07:34:01 -0500 GHRS